



Exscien Corporation



Contact: Ker Ferguson, CEO **Location:** Louisville, KY **Email:** kferguson@exsciencorporation.com **Tel:** 251.654.1252 **Website:** <http://www.exsciencorp.com>



Company Profile

Industry Sector: Bio-pharmaceuticals

Company Overview: Exscien (founded 2011) is currently in pre-clinical development of its patented lead drug candidate for use against various indications. Awarded NIH SBIR Phase I and II grants totaling \$3.7 million.

Target Market(s): mtDNA damage initiates the critical path and progression of many disease states e.g., ischemic stroke, acute and chronic heart failure, cancer, diabetes, macular degeneration, neurodegenerative diseases, arthritis, reperfusion injury, sepsis, etc. – all which represent target market applications.



Key Value Drivers

Technology*: A fusion protein construct that traffics DNA repair enzymes to the mitochondria to repair mtDNA damage and restore normal cellular metabolic function.

Competitive Advantage: A platform technology with a unique mechanism of action, which targets and repairs mitochondrial dysfunction - reversing the process and signaling mechanisms linked with cell death, disease progression and tumor development.

Plan & Strategy: Company will establish scalable production capability and perform Phase 1 and 2 clinical trials; then proceed to out-license to pharma within specific fields of use.



Management

W. Ker Ferguson, MBA, PhD (CEO)

- 20 Years experience in early-stage, technology transfer and product development in US and abroad

Glenn Wilson, PhD (CSO)

- Inventing scientist and patent holder
- Professor Emeritus, University of South Alabama
- Recognized mtDNA specialist and Department Chair

Mark Gillespie, PhD, Chair, Dept of Pharmacology, Univ. of South Alabama (Exscien Chief of Academic Liaison)
Joanna Mroczkowska, PhD (Lab and Production Operations Manager – Bioprocessing Specialist) Borys Troyanovsky, PhD (Lab Technician)



Product Pipeline

1. Medical Device: Organ transplant preservation fluid – currently classified as a medical device by FDA – with a potentially shorter and easier regulatory path to market. Our protein enhances organ longevity and reduces transplant complications (i.e., graft dysfunction and reperfusion injury).

2. Therapeutic Applications: In murine models, the fusion protein has demonstrated the ability to reduce: (a) infarct volume and overall tissue damage by upwards of 56% in the setting of acute myocardial infarction and ischemic stroke; (b) primary tumor growth by 30% (by volume) with reduction of metastasis by up to 70% (loci and volume) in breast cancer.